Resveratrol-mediated reversal of tumor multi-drug resistance

Current Drug Metabolism

Volumn 15, Issue 7, 2014, Pages 703-710

  Hu, Yutong ^a   Li, Chuangang ^a   Li, Hong ^a   Li, Molin ^a   Shu, Xiaohong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

ATP binding cassette transporters; Breast cancer resistance protein; Multi drug resistance; Multi drug resistance associated protein; P glycoprotein; Resveratrol

Indexed keywords

ABC TRANSPORTER; AMIODARONE; BENZBROMARONE; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN; DIETHYLSTILBESTROL; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; FUMITREMORGIN C; GENISTEIN; INDOMETACIN; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; PACLITAXEL; PANTOPRAZOLE; PROBENECID; RESVERATROL; SIRTUIN 1; STAT3 PROTEIN; SULFINPYRAZONE; TENIPOSIDE; VALSPODAR; VERAPAMIL; VINCA ALKALOID; VINCRISTINE; ABCG2 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; STILBENE DERIVATIVE; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; DOWN REGULATION; DRUG STRUCTURE; HUMAN; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; STILBENES;

EID: 84926301219     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200215666140926153522     Document Type: Article

References (102)

1. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1. Annu. Rev. Pharmacol. Toxicol., 1999, 39 (1), 361-398.
2. Berginc, K.; Kristl, A. The mechanisms responsible for garlic-drug interactions and their in vivo relevance. Curr. Drug Metab., 2013, 14 (1), 90-101.
3. Cantore, M.; Capparelli, E.; Berardi, F.; Perrone, R.; Antonio Colabufo, N. Clinical pharmacokinetic and metabolism of PET radiotracers for imaging P-glycoprotein in chemoresistant tumor of colorectal cancer. Curr. Drug Metab., 2011, 12 (10), 985-988.
4. Szakács, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug. Discov., 2006, 5 (3), 219-234.
5. Honorat, M.; Falson, P.; Terreux, R.; Di Pietro, A.; Dumontet, C.; Payen, L. Multidrug resistance ABC transporter structure predictions by homology modeling approaches. Curr. Drug Metab., 2011, 12 (3), 268-277.
6. AJ, Darby, R.; Callaghan, R.; M McMahon, R. P-glycoprotein inhibition: the past, the present and the future. Curr. Drug Metab., 2011, 12 (8), 722-731.
7. Sharom, F.J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 2008, 9 (1), 105-127.
8. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 2003, 55 (1), 3-29.
9. Planas, J.M.; Alfaras, I.; Colom, H.; Juan, M.E. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch. Biochem. Biophys., 2012, 527 (2), 67-73.
10. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 1993, 62 (1), 385-427.
11. Imai, Y.; Tsukahara, S.; Asada, S.; Sugimoto, Y. Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res., 2004, 64 (12), 4346-4352.
12. Li, X.; Choi, J.S. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int. J. Pharm., 2007, 337 (1), 188-193.
13. Velentzis, L.S.; Woodside, J.V.; Cantwell, M.M.; Leathem, A.J.; Keshtgar, M.R. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. Eur. J. Cancer, 2008, 44 (13), 1799-1806.
14. Beaudeux, J.L.; Nivet-antoine, V.; Giral, P. Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome? Curr. Opin. Clin. Nutr. Metab. Care, 2010, 13 (6), 729-736.
15. Gusman, J.; Malonne, H.; Atassi, G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis, 2001, 22 (8), 1111-1117.
16. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.; Fong, H.H.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G.; Moon, R.C.; Pezzuto, J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275, 218-220.
17. Zhao, W.; Bao, P.; Qi, H.; You, H. Resveratrol down-regulates survivin and induces apoptosis in human multidrug-resistant SPCA-1/CDDP cells. Oncol. Rep., 2010, 23 (1), 279-286.
18. Holmes-McNary, M.; Baldwin, A.S. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IB kinase. Cancer Res., 2000, 60 (13), 3477-3483.
19. Opipari, A.W.; Tan, L.; Boitano, A.E.; Sorenson, D.R.; Aurora, A.; Liu, J.R., Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res., 2004, 64 (2), 696-703.
20. Al-Abd, A.M.; Mahmoud, A.M.; El-Sherbiny, G.A.; El-Moselhy, M.A.; Nofal, S.M.; El-Latif, H.A.; El-Eraky, WI.; El-Shemy, HA. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif., 2011, 44 (6), 591-601.
21. Quan, F.; Pan, C.; Ma, Q.; Zhang, S.; Yan, L. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed. Pharmacother., 2008, 62 (9), 622-629.
22. Wesolowska, O.; Wisniewsk, J.; Bielawska-Pohl, A.; Paprocka, M.; Duarte, N.; Ferreira, M.J.; D. Dus, K. Michalak K. Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells. AntiCancer Res., 2010, 30 (11), 4587-4593.
23. Hsieh, T.C.; Juan, G.; Darzynkiewicz, Z.; Wu, J.M. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21WAF1/CIP1, and suppresses cultured bovine pulmonary artery endothelial cell prolif by perturbing progression through S and G2. Cancer Res., 1999, 59 (11), 2596-2601.
24. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta., 1976, 455 (1), 152-162.
25. Schinkel, A.H. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev., 1999, 36 (2), 179-194.
26. Huisman, M.T.; Smit, J.W.; Schinkel, A.H. Significance of Pglycoprotein for the pharmacology and clinical use of HIV protease inhibitors. Aids, 2000, 14 (3), 237-242.
27. Litman, T.; Druley, T.; Stein, W.; Bates, S. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci., 2001, 58 (7), 931-959.
28. Kusuhara, H.; Sugiyama, Y. Role of transporters in the tissueselective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control. Release, 2002, 78 (1), 43-54.
29. Siegsmund, M.; Brinkmann, U.; Scháffeler, E.; Weirich, G.; Schwab, M.; Eichelbaum, M.; Fritz, P.; Burk, O.; Decker, J.; Alken, P. Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol., 2002, 13 (7), 1847-1854.
30. Bergman, A.; Pinedo, H.; Talianidis, I.; Veerman, G.; Loves, W.; Van der Wilt, C.; Peters, G. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated proteinoverexpressing human cancer cell lines. Br. J. Cancer., 2003, 88 (12), 1963-1970.
31. Lee, W.; Kim, R.B. Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 137-166.
32. Nomura, T.; Yamamoto, H.; Mimata, H.; Shitashige, M.; Shibasaki, F.; Miyamoto, E.; Nomura, Y. Enhancement by cyclosporin A of taxol-induced apoptosis of human urinary bladder cancer cells. Urol. Res., 2002, 30 (2), 102-111.
33. Watanabe, T.; Tsuge, H.; Oh-Hara, T.; Naito, M.; Tsuruo, T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta. Oncol., 1995, 34 (2), 235-241.
34. Maliepaard, M.; van Gastelen, M.A.; Tohgo, A.; Hausheer, F.H.; van Waardenburg, R.C.; de Jong, L.A.; Pluim, D.; Beijnen, J.H.; Schellens, J.H. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using nonsubstrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res., 2001, 7 (4), 935-941.
35. Malingre, M.; Beijnen, J.; Rosing, H.; Koopman, F.; Jewell, R.; Paul, E.; Huinink, W.T.B.; Schellens, J. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer., 2001, 84 (1), 42-47.
36. Mistry, P.; Stewart, A.J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J.A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res., 2001, 61 (2), 749-758.
37. Pusztai, L.; Wagner, P.; Ibrahim, N.; Rivera, E.; Theriault, R.; Booser, D.; Symmans, F.W.; Wong, F.; Blumenschein, G.; Fleming, D.R. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 2005, 104 (4), 682-691.
38. Wen, Z.Z.; Hao, C.Y.; Wei, H.L.; Su, H.X. Resveratrol overcomes apoptosis resistance in multidrug-resistant K562/ADM cells by down-regulating expression of mdr1 gene and its product Pglycoprotein. Pharmacology and Clinics of Chinese Materia Medica.(Chinese), 2008, 24(3),10-13.
39. Nabekura, T.; Kamiyama, S.; Kitagawa, S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun., 2005, 327 (3), 866-870.
40. Choi, J.S.; Choi, B.C.; Kang, K.W. Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie, 2009, 64 (1), 49-52.
41. Anthony, V.; Skach, W.R. Molecular mechanism of P-glycoprotein assembly into cellular membranes. Curr. Protein Pept. Sci., 2002, 3 (5), 485-501.
42. Cole, S.; Bhardwaj, G.; Gerlach, J.; Mackie, J.; Grant, C.; Almquist, K.; Stewart, A.; Kurz, E.; Duncan, A.; Deeley, R. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 1992, 258 (5088), 1650-1654.
43. Cole, S.P.; Sparks, K.E.; Fraser, K.; Loe, D.W.; Grant, C.E.; Wilson, G.M.; Deeley, R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 1994, 54 (22), 5902-5910.
44. Müller, M.; Meijer, C.; Zaman, G.; Borst, P.; Scheper, R.J.; Mulder, N.H.; De Vries, E.; Jansen, P. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA, 1994, 91 (26), 13033-13037.
45. Evers, R.; Zaman, G.; van Deemter, L.; Jansen, H.; Calafat, J.; Oomen, L.; Elferink, R.O.; Borst, P.; Schinkel, A.H. Basolateral localization and export activity of the human multidrug resistanceassociated protein in polarized pig kidney cells. J. Clin. Invest., 1996, 97 (5), 1211-1218.
46. Manciu, L.; Chang, X.B.; Buyse, F.; Hou, Y.X.; Gustot, A.; Riordan, J.R.; Ruysschaert, J.M. Intermediate structural states involved in MRP1-mediated drug transport Role of Glutathione. J. Biol. Chem., 2003, 278 (5), 3347-3356.
47. Hooijberg, J.H.; Broxterman, H.J.; Kool, M.; Assaraf, Y.G.; Peters, G.J.; Noordhuis, P.; Scheper, R.J.; Borst, P.; Pinedo, H.M.; Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res., 1999, 59 (11), 2532-2535.
48. Evers, R.; De Haas, M.; Sparidans, R.; Beijnen, J.; Wielinga, P.; Lankelma, J.; Borst, P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer., 2000, 83 (3), 375-383.
49. O'Connor R., Heenan M., Connolly L., Larkin A., Clynes M. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res., 2004, 24 (2A), 457-464.
50. Haimeur, A.; Conseil, G.; Deeley, R.; Cole, S. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab., 2004, 5 (1), 21-53.
51. Henry, C.; Vitrac, X.; Decendit, A.; Ennamany, R.; Krisa, S.; Mérillon, J.M., Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the apical membrane of human intestinal Caco-2 cells. J. Agric. Food Chem., 2005, 53 (3), 798-803.
52. Maier-Salamon, A.; Hagenauer, B.; Wirth, M.; Gabor, F.; Szekeres, T.; Jäger, W. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res., 2006, 23 (9), 2107-2115.
53. Kweon, S.H.; Song, J.H.; Kim, T.S. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem. Biophys. Res. Commun., 2010, 395 (1), 104-110.
54. Kim, J.H.; Chen, C.; Tony Kong, A.N. Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Arch. Biochem. Biophys., 2011, 512 (2), 160-166.
55. Maier-Salamon, A.; Hagenauer, B.; Reznicek, G.; Szekeres, T.; Thalhammer, T.; Jäger, W. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. J. Pharm. Sci., 2008, 97 (4), 1615-1628.
56. Shu, X.H.; Li, H.; Sun, Z.; Wu, M.L.; Ma, J.X.; Wang, J.M.; Wang, Q.; Sun, Y.; Fu, Y.S.; Chen, X.Y. Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem. Pharmacol., 2010, 79 (10), 1516-1525.
57. Juan, M.E.; González-Pons, E.; Planas, J.M. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J. Nutr., 2010, 140 (3), 489-495.
58. Kim, T.H.; Shin, Y.J.; Won, A.J.; Lee, B.M.; Choi, W.S.; Jung, J.H.; Chung, H.Y.; Kim, H.S. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim. Biophys. Acta., 2014, 1840 (1), 615-625.
59. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 1998, 95 (26), 15665-15670.
60. Lee, J.S.; Scala, S.; Matsumoto, Y.; Dickstein, B.; Robey, R.; Zhan, Z.; Altenberg, G.; Bates, S.E. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J. Cell Biochem., 1997, 65 (4), 513-526.
61. Allikmets, R.; Schriml, L.M.; Hutchinson, A.; Romano-Spica, V.; Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 1998, 58 (23), 5337-5339.
62. Meissner, K.; Heydrich, B.; Jedlitschky, G.; zu Schwabedissen, H.M.; Mosyagin, I.; Dazert, P.; Eckel, L.; Vogelgesang, S.; Warzok, R.W.; Böhm, M. The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J. Histochem. Cytochem., 2006, 54 (2), 215-221.
63. Ni, Z.; Bikadi, Z.; Rosenberg, M. F.; Mao, Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr. Drug Metab., 2010, 11 (7), 603-617.
64. Diestra, J.E.; Condom, E.; Del Muro, X.G.; Scheffer, G.L.; Perez, J.; Zurita, A.J.; Munoz-Segui, J.; Vigues, F.; Scheper, R.J.; Capella, G. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J. Urol., 2003, 170 (4), 1383-1387.
65. de Bruin, M.; Miyake, K.; Litman, T.; Robey, R.; Bates, S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett., 1999, 146 (2), 117-126.
66. Allen, J.D.; Brinkhuis, R.F.; Wijnholds, J.; Schinkel, A.H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res., 1999, 59 (17), 4237-4241.
67. Sugimoto, Y.; Tsukahara, S.; Imai, Y.; Ueda, K.; Tsuruo, T. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists1. Mol. Cancer Ther., 2003, 2 (1), 105-112.
68. Cooray, H.C.; Janvilisri, T.; van Veen, H.W.; Hladky, S.B.; Barrand, M.A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun., 2004, 317 (1), 269-275.
69. Murakami, T.; Takano, M., Intestinal efflux transporters and drug absorption. Exp. Opin. Drug Metab. Toxicol., 2008, 4 (7), 923-939.
70. Hsu, P.C.; Hung, H.C.; Liao, Y.F.; Liu, C.C.; Tsay, G.J.; Liu, G.Y. Ornithine decarboxylase attenuates leukemic chemotherapy drugsinduced cell apoptosis and arrest in human promyelocytic HL-60 cells. Leuk. Res., 2008, 32 (10), 1530-1540.
71. Sun, C.; Hu, Y.; Liu, X.; Wu, T.; Wang, Y.; He, W.; Wei, W. Resveratrol downregulates the constitutional activation of nuclear factor-κB in multiple myeloma cells, leading to suppression of prolif eration and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet. Cytogenet., 2006, 165 (1), 9-19.
72. Yu, H.; Pan, C.; Zhao, S.; Wang, Z.; Zhang, H.; Wu, W. Resveratrol inhibits tumor necrosis factor-κ-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed. Pharmacother., 2008, 62 (6), 366-372.
73. Riles, W.L.; Erickson, J.; Nayyar, S.; Atten, M.J.; Attar, B.M.; Holian, O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J. Gastroenterol., 2006, 12 (35), 5628-5634
74. Hu, Y.; Rahlfs, S.; Mersch-Sundermann, V.; Becker, K. Resveratrol modulates mRNA transcripts of genes related to redox metabolism and Cell Prolif in non-small-cell lung carcinoma cells. Biol. Chem., 2007, 388 (2), 207-219.
75. Price, N.L.; Gomes, A.P.; Ling, A.J.; Duarte, F.V.; Martin-Montalvo, A.; North, B.J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J.S.; Hubbard, B.P.; Varela, A.T.; Davis, J.G.; Varamini, B.; Hafner, A.; Moaddel, R.; Rolo, A.P.; Coppari, R.; Palmeira, C.M.; de Cabo, R.; Baur, J.A.; Sinclair, D.A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab., 2012, 15(5), 675-690.
76. Knutson, M.D.; Leeuwenburgh, C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev., 2008, 66(10), 591-596.
77. Bourguignon, L.Y.; Xia, W.; Wong, G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates κ-catenin signaling and NFκB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem., 2009, 284 (5), 2657-2671.
78. Bowman, T.; Garcia, R.; Turkson, J.; Jove, R. STATs in oncogenesis. Oncogene, 2000, 19 (21), 2474-2488.
79. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 2009, 9 (11), 798-809.
80. Inoue, H.; Ogawa, W.; Ozaki, M.; Haga, S.; Matsumoto, M.; Furukawa, K.; Hashimoto, N.; Kido, Y.; Mori, T.; Sakaue, H. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med., 2004, 10 (2), 168-174.
81. Nie, Y.; Erion, D.M.; Yuan, Z.; Dietrich, M.; Shulman, G.I.; Horvath, T.L.; Gao, Q. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nature cell biology, 2009, 11 (4), 492-500.
82. Yu, H.; Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer, 2004, 4 (2), 97-105.
83. Abdulghani, J.; Gu, L.; Dagvadorj, A.; Lutz, J.; Leiby, B.; Bonuccelli, G.; Lisanti, M.P.; Zellweger, T.; Alanen, K.; Mirtti, T. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol., 2008, 172 (6), 1717-1728.
84. Leeman-Neill, R.J.; Wheeler, S.E.; Singh, S.V.; Thomas, S.M.; Seethala, R.R.; Neill, D.B.; Panahandeh, M.C.; Hahm, E.R.; Joyce, S.C.; Sen, M. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis, 2009, 30 (11), 1848-1856.
85. Yang, C.; Hornicek, F.J.; Wood, K.B.; Schwab, J.H.; Choy, E.; Mankin, H.; Duan, Z. Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. Spine, 2010, 35 (18), 1668-1675.
86. Duan, Z.; Foster, R.; Bell, D.A.; Mahoney, J.; Wolak, K.; Vaidya, A.; Hampel, C.; Lee, H.; Seiden, M.V. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res., 2006, 12 (17), 5055-5063.
87. Alas, S.; Bonavida, B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res., 2003, 9 (1), 316-326.
88. Nielsen, M.; Nissen, M.H.; Gerwien, J.; Zocca, M.B.; Rasmussen, H.M.; Nakajima, K.; Röpke, C.; Geisler, C.; Kaltoft, K.; Ødum, N. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood, 2002, 99 (3), 973-977.
89. Huang, S.; Chen, M.; Shen, Y.; Shen, W.; Guo, H.; Gao, Q.; Zou, X. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett., 2012, 315 (2), 198-205.
90. Shu, X.H.; Li, H.; Sun, X.X.; Wang, Q.; Sun, Z.; Wu, M.L.; Chen, X.Y.; Li, C.; Kong, Q.Y.; Liu, J. Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS One. 2011, 6(11), e27484.
91. Bhardwaj, A.; Sethi, G.; Vadhan-Raj, S.; Bueso-Ramos, C.; Takada, Y.; Gaur, U.; Nair, A.S.; Shishodia, S.; Aggarwal, B.B. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 2007, 109 (6), 2293-2302.
92. Wu, S.L.; Yu, L.; Pan, C.E.; Jiao, X.Y.; Lv, Y.; Fu, J.; Meng, K.W. Apoptosis of lymphocytes in allograft in a rat liver transplantation model induced by resveratrol. Pharmacol. Res., 2006, 54 (1), 19-23.
93. Deng, L.; Lin-Lee, Y.C.; Claret, F.X.; Kuo, M.T. 2-Acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-κB pathway. J. Biol. Chem., 2001, 276 (1), 413-420.
94. Fantappiè, O.; Masini, E.; Sardi, I.; Raimondi, L.; Bani, D.; Solazzo, M.; Vannacci, A.; Mazzanti, R. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology, 2002, 35 (4), 843-852.
95. Lamba, J.; Strom, S.; Venkataramanan, R.; Thummel, K.E.; Lin, Y.S.; Liu, W.; Cheng, C.; Lamba, V.; Watkins, P.B.; Schuetz, E. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther., 2006, 79 (4), 325-338.
96. Kuo, M.T.; Liu, Z.; Wei, Y.; Lin-Lee, Y.C.; Tatebe, S.; Mills, G.B.; Unate, H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene, 2002, 21 (13), 1945-1954.
97. Tomiyasu, H.; Watanabe M.; Sugita K.; Goto-Koshino Y.; Fujino Y.; Ohno K.; Sugano S.; Tsujimoto H. Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines. Anticancer Res., 2013, 33 (12), 5317-5323.
98. Misra, S.; Ghatak, S.; Toole, B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem., 2005, 280 (21), 20310-20315.
99. Lee, J.T.; Steelman, L.S.; McCubrey, J.A. Phosphatidylinositol 3κ-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res., 2004, 64 (22), 8397-8404.
100. Zhan, M.; Yu, D.; Liu, J.; Hannay, J.; Pollock, R.E. Transcriptional repression of protein kinase Cκ via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J. Biol. Chem., 2005, 280 (6), 4825-4833.
101. Frank, D.A.; Mahajan, S.; Ritz, J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest., 1997, 100 (12), 3140-3148.
102. Catlett-Falcone, R.; Landowski, T.H.; Oshiro, M.M.; Turkson, J.; Levitzki, A.; Savino, R.; Ciliberto, G.; Moscinski, L.; Fernández-Luna, J.L.; Nuñez, G. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 1999, 10 (1), 105-115.